 This is an open-label, non-randomized phase II paediatric study. In this study, eligible patients will receive autologous T cells transduced with the lentiviral vector pLTG1563 MB-CART19.1 at a doesage of 2x10e6 2x10e7 CAR-transduced T cellskg. 